# Juvenile Psoriatic Arthritis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/juvenile-psoriatic-arthritis

> 2 upcoming FDA catalysts in juvenile Psoriatic Arthritis: Sotyktu (deucravacitinib, BMY) on Mar to Jun 2030 (topline data readout); Sotyktu (deucravacitinib, BMY) on March 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 2026 | [AMJEVITA® (adalimumab) primary completion](https://sec-api.dev/pdufa/adalimumab) | ABBV | Juvenile Psoriatic Arthritis | delayed | "NCT06100744 (A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100744)) |
| Sep to Dec 2026 | [AMJEVITA® (adalimumab) topline data readout](https://sec-api.dev/pdufa/adalimumab) | ABBV | Juvenile Psoriatic Arthritis | scheduled | "NCT06100744 (A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100744)) |
| Mar to Jun 2030 | [Sotyktu (deucravacitinib) topline data readout](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Juvenile Psoriatic Arthritis | scheduled | "NCT06869551 (A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06869551)) |
| March 2030 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Juvenile Psoriatic Arthritis | scheduled | "NCT06869551 (A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06869551)) |

## Drugs

- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Sotyktu (deucravacitinib)](https://sec-api.dev/pdufa/deucravacitinib) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/juvenile-psoriatic-arthritis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Juvenile Psoriatic Arthritis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/juvenile-psoriatic-arthritis

```bibtex
@misc{secapidev_indications_juvenile_psoriatic_arthritis_20261116,
  title        = {Juvenile Psoriatic Arthritis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/juvenile-psoriatic-arthritis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_juvenile_psoriatic_arthritis_20261116","title":"Juvenile Psoriatic Arthritis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/juvenile-psoriatic-arthritis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
